BlossomHill Therapeutics, Inc. Stock

Stocks

Market Closed - Nasdaq 00:00:00 30/09/2026 +04			5-day change	1st Jan Change
21.37 ^USD	+0.14%		-15.37%	-

09-29	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
09-21	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI

NasdaqUSD

Markets		Quality
Nasdaq	BLSM	Delayed
CBOE	BLSM	Real-time

09-29	Blossomhill Therapeutics, Inc. Presents Preclinical Data on Novel Pan-KRAS Inhibitor, Bh-501284, At the AACR Conference on Pancreatic Cancer	CI
09-21	BlossomHill Therapeutics, Inc.(NasdaqGS:BLSM) added to S&P TMI Index	CI
09-18	BlossomHill Therapeutics Q2 Loss Widens	MT
09-18	Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share	MT
09-18	BlossomHill Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 Solara Trial Demonstrating Anti-Tumor Activity of Omni-EGFR Inhibitor BH-30643 in EGFR C797s-Positive NSCLC	CI
09-15	BlossomHill Drug Shows 45% Response Rate in Lung Cancer Trial	MT
09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT
08-18	BlossomHill Says BH-30643 Gets FDA Fast Track Designation in Non-Small Cell Lung Cancer	MT
08-18	Blossomhill Therapeutics Receives Fda Fast Track Designation for Bh-30643 for Treatment of Advanced Egfr C797s-Positive Nsclc	CI

09-01	Leerink Partners Initiates BlossomHill Therapeutics at Outperform, $36 Price Target	MT
09-01	JPMorgan Initiates BlossomHill Therapeutics at Overweight	MT
09-01	Guggenheim Initiates BlossomHill Therapeutics at Buy With $30 Price Target	MT
09-01	HC Wainwright Initiates BlossomHill Therapeutics at Buy With $35 Price Target	MT

09-28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	GL
09-28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer	AQ
09-18	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results	GL
09-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer	GL
09-03	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference	GL

Manager	Title	Age	Since
Jing Rong Jean Cui CEO	Chief Executive Officer	62	01/06/2020
Jason Keyes DFI	Director of Finance/CFO	55	01/05/2025
Zachary Zimmerman CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jing Rong Jean Cui BRD	Director/Board Member	62	01/06/2020
Bihua Chen BRD	Director/Board Member	57	01/02/2021
Yi Shan Li CHM	Chairman	61	01/06/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/08/26	Sundeep Agrawal	Conversion	Director	1,157,048	3.6917%
10/08/26	Cormorant Asset Management LP	Conversion	Company	6,915,568	22.0651%
10/08/26	Vincent Liptak	Buy	General Counsel	47,574	0.1518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLOSSOMHILL THERAPEUTICS, INC.	+0.14%	-15.37%	-	-	678M
LONZA GROUP AG	-0.03%	+3.77%	+12.35%	+37.22%	49.06B
IQVIA HOLDINGS INC.	-0.73%	-0.41%	+48.84%	+36.72%	44.6B
REVOLUTION MEDICINES, INC.	+1.36%	+6.03%	+343.85%	+638.73%	43.24B
BEONE MEDICINES AG	-0.47%	-0.76%	+9.75%	+103.07%	41.73B
CELLTRION, INC.	+0.34%	+0.22%	+5.18%	+47.36%	29.93B
MEDPACE HOLDINGS, INC.	+1.00%	-1.28%	+24.23%	+156.93%	17.19B
EUROFINS SCIENTIFIC SE	-3.20%	-3.50%	+25.33%	+42.43%	15.54B
TEMPUS AI, INC.	-2.94%	+6.98%	+5.10%	-	15.35B
ASCENDIS PHARMA A/S	-0.86%	-4.00%	-	-	15.11B
Average	-0.54%	-0.52%	+59.33%	+151.78%	27.24B
Weighted average by Cap.	-0.28%	+1.75%	+74.43%	+166.43%